FAS Wealth Partners’s Dermata Therapeutics DRMA Stock Holding History

FAS Wealth Partners’s Portfolio DRMA Stock Details DRMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5	Closed	-$5.19K	–	424
2022 Q4	$5.19K	Buy	+5	New	+$6.27K	﹤0.01%	395

Other funds holding DRMA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

FAS Wealth Partners's DRMA Position: Q1 2023 in Review

FAS Wealth Partners sold out of Dermata Therapeutics (DRMA) in Q1 2023, closing a stake of 5 shares — an estimated $5.19K sold.

FAS Wealth Partners first reported a position in DRMA in Q4 2022 and held it in 1 quarter. The position peaked at $5.19K in Q4 2022. 4 funds tracked by Wall St. Rank hold DRMA as of Q1 2023.

FAS Wealth Partners reported no remaining Dermata Therapeutics position as of Q1 2023 after selling out during the quarter.
FAS Wealth Partners sold 5 Dermata Therapeutics shares in Q1 2023, an estimated $5.19K.
FAS Wealth Partners first reported a position in Dermata Therapeutics in Q4 2022 and held it in 1 quarter.
FAS Wealth Partners's Dermata Therapeutics position peaked at $5.19K in Q4 2022.
4 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q1 2023.

Based on FAS Wealth Partners's 13F filing for Q1 2023, filed 11 May 2023.